EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bladder EpiCheck clinical utility to predict BCG response in non‐muscle‐invasive bladder cancer

Fiorella L Roldán iD, Mercedes Ingelmo-Torres, Claudia Mercader iD, Marcel Figueras, Bernat Padullés, María Angeles Durán, Josep L Carrasco, María José Ribal, Agustín Franco, Laura Izquierdo iD, Antonio Alcaraz, Lourdes Mengual

BJU International · 2025-10 · 136 (4) · 682-689

DOI: 10.1111/bju.16697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 06.03.2025. Verfasst von Fiorella L Roldán und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Neoplasm Recurrence, Local, Adjuvants, Immunologic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nucleix.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the performance of Bladder Epicheck® (BE; Nucleix Ltd., Rehovot, Israel) in predicting tumour recurrence and bacillus Calmette–Guérin (BCG) failure during the first year after induction treatment. Patients and methods Prospective study including 65 patients with non‐muscle‐invasive bladder cancer treated with BCG between 2018 and 2021. Urine samples analysed with BE were collected before and after BCG induction. Logistic binary regression was used to assess the association between clinical and pathological variables and BE results with tumour recurrence and BCG failure during the first year after induction treatment.

Results

During follow‐up, 16 (24.6%) patients experienced a bladder cancer event, 11 (68.8%) of which were BCG failure (high‐grade recurrence) and five (31.2%) were low‐grade recurrences. The median (range) time to overall recurrence was 7.3 (3.8–17.4) months. A significant association was found between the risk of tumour recurrence/BCG failure and post‐BCG cystoscopy (odds ratio [OR] 10.0; P < 0.001 and OR 13.1; P < 0.001, respectively), post‐BCG BE result (OR 16.9; P < 0.001 and OR 33.1; P < 0.001, respectively) and pre/post‐BCG EpiScore value variation (OR 14.4; P = 0.001 and OR 7.1; P = 0.018, respectively). A nomogram including these three variables outperformed the Club Urológico Español de Tratamiento Oncológico (CUETO) risk tables to predict any bladder cancer event after BCG induction (area under the curve 95.1% vs 67.1%). Result validation in a larger and independent series is needed.

Conclusions

The BE post‐BCG status and variations in EpiScore values can help us identify patients at higher risk of any bladder cancer event and BCG failure promptly. These data can have an impact on disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsBCG VaccineNeoplasm Recurrence, LocalAdjuvants, ImmunologicHumansMaleFemaleAgedProspective StudiesMiddle AgedAged, 80 and overNeoplasm InvasivenessPredictive Value of TestsTreatment FailureNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

BCG responseBacillus Calmette–Guérin (BCG)bladder EpiCheckbladder cancermethylation biomarkerspredictive biomarkersurine

Substanzen

BCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • Laboratori i Servei d'Urologia, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Genètica i Tumors Urològics, Fundació de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.
  • Unitat de Bioestadística, Departament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
  • Unitat de Genètica, Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.

ORCID-Profile: Fiorella L Roldán, Claudia Mercader, Laura Izquierdo

Förderung

  • Nucleix

Zitieren

APA

Roldán, F. L., Ingelmo-Torres, M., Mercader, C., Figueras, M., Padullés, B., Durán, M. A., Carrasco, J. L., Ribal, M. J., Franco, A., Izquierdo, L., Alcaraz, A., & Mengual, L. (2025). Bladder EpiCheck clinical utility to predict BCG response in non‐muscle‐invasive bladder cancer. BJU International, 136(4), 682-689. https://doi.org/10.1111/bju.16697

Vancouver

Roldán FL, Ingelmo-Torres M, Mercader C, Figueras M, Padullés B, Durán MA, et al. Bladder EpiCheck clinical utility to predict BCG response in non‐muscle‐invasive bladder cancer. BJU International. 2025;136(4):682-689. doi:10.1111/bju.16697

BibTeX
@article{Roldn2025,
  author = {Roldán, Fiorella L and Ingelmo-Torres, Mercedes and Mercader, Claudia and Figueras, Marcel and Padullés, Bernat and Durán, María Angeles and Carrasco, Josep L and Ribal, María José and Franco, Agustín and Izquierdo, Laura and Alcaraz, Antonio and Mengual, Lourdes},
  title = {Bladder EpiCheck clinical utility to predict BCG response in non‐muscle‐invasive bladder cancer},
  journal = {BJU International},
  year = {2025},
  volume = {136},
  number = {4},
  pages = {682--689},
  doi = {10.1111/bju.16697}
}
Kostenlos starten →